Integration of ERG gene mapping and gene‐expression profiling identifies distinct categories of human prostate cancer

To integrate the mapping of ERG alterations with the collection of expression microarray (EMA) data, as previous EMA analyses have failed to consider the genetic heterogeneity and complex patterns of ERG alteration frequently found in cancerous prostates.

[1]  L. Pardo,et al.  Monoclonal antibody blockade of the human Eag1 potassium channel function exerts antitumor activity. , 2007, Cancer research.

[2]  G. Jenster,et al.  TMPRSS2:ERG fusion by translocation or interstitial deletion is highly relevant in androgen-dependent prostate cancer, but is bypassed in late-stage androgen receptor-negative prostate cancer. , 2006, Cancer research.

[3]  D. Bostwick,et al.  Chromosomal anomalies in prostatic intraepithelial neoplasia and carcinoma detected by fluorescence in situ hybridization. , 1995, Cancer research.

[4]  R. Eeles,et al.  Diversity of TMPRSS2-ERG fusion transcripts in the human prostate , 2007, Oncogene.

[5]  P. Singh,et al.  A potential paradox in prostate adenocarcinoma progression: oestrogen as the initiating driver. , 2008, European journal of cancer.

[6]  R. Tibshirani,et al.  Gene expression profiling identifies clinically relevant subtypes of prostate cancer. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[7]  L. Liotta,et al.  Evidence of independent origin of multiple tumors from patients with prostate cancer. , 1998, Journal of the National Cancer Institute.

[8]  Rosalind Eeles,et al.  Transcription factor E2F3 overexpressed in prostate cancer independently predicts clinical outcome , 2004, Oncogene.

[9]  Y Pawitan,et al.  TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort , 2007, Oncogene.

[10]  Ash A. Alizadeh,et al.  Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling , 2000, Nature.

[11]  Gordon K. Smyth,et al.  limma: Linear Models for Microarray Data , 2005 .

[12]  U. Stenman,et al.  Increased expression of tumor-associated trypsin inhibitor, TATI, in prostate cancer and in androgen-independent 22Rv1 cells. , 2007, European urology.

[13]  M. Becich,et al.  Gene expression alterations in prostate cancer predicting tumor aggression and preceding development of malignancy. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  S. Varambally,et al.  Characterization of TMPRSS2:ETV5 and SLC45A3:ETV5 gene fusions in prostate cancer. , 2008, Cancer research.

[15]  M. Marberger,et al.  Predictability and significance of multifocal prostate cancer in the radical prostatectomy specimen. , 1999, Techniques in urology.

[16]  Debashis Ghosh,et al.  Comprehensive assessment of TMPRSS2 and ETS family gene aberrations in clinically localized prostate cancer , 2007, Modern Pathology.

[17]  C. Roehrborn,et al.  Prospective randomized comparison of high energy transurethral microwave thermotherapy versus alpha-blocker treatment of patients with benign prostatic hyperplasia. , 1999, The Journal of urology.

[18]  J. Tchinda,et al.  Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. , 2006, Science.

[19]  T. Golub,et al.  Estrogen-dependent signaling in a molecularly distinct subclass of aggressive prostate cancer. , 2008, Journal of the National Cancer Institute.

[20]  J. Mesirov,et al.  Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. , 1999, Science.

[21]  J. Veltman,et al.  Loss of a small region around the PTEN locus is a major chromosome 10 alteration in prostate cancer xenografts and cell lines , 2004, Genes, chromosomes & cancer.

[22]  D. Bostwick,et al.  Independent origin of multiple foci of prostatic intraepithelial neoplasia , 1998, Cancer.

[23]  John T. Wei,et al.  Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression. , 2005, Cancer cell.

[24]  S. Dhanasekaran,et al.  Delineation of prognostic biomarkers in prostate cancer , 2001, Nature.

[25]  S. Dhanasekaran,et al.  Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer , 2007, Nature.

[26]  M. Daly,et al.  PGC-1α-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes , 2003, Nature Genetics.

[27]  S. Nordling,et al.  High tissue expression of tumour‐associated trypsin inhibitor (TATI) associates with a more favourable prognosis in gastric cancer , 2005, Histopathology.

[28]  Gordon K Smyth,et al.  Statistical Applications in Genetics and Molecular Biology Linear Models and Empirical Bayes Methods for Assessing Differential Expression in Microarray Experiments , 2011 .

[29]  C. Cooper,et al.  A Gene Expression Signature Associated with Metastatic Outcome in Human Leiomyosarcomas , 2004, Cancer Research.

[30]  Colin Campbell,et al.  The Latent Process Decomposition of cDNA Microarray Data Sets , 2005, TCBB.

[31]  R. Tibshirani,et al.  Repeated observation of breast tumor subtypes in independent gene expression data sets , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[32]  A. Evans,et al.  Three-color FISH analysis of TMPRSS2/ERG fusions in prostate cancer indicates that genomic microdeletion of chromosome 21 is associated with rearrangement. , 2006, Neoplasia.

[33]  U. Stenman,et al.  Biochemistry and Clinical Role of Trypsinogens and Pancreatic Secretory Trypsin Inhibitor , 2006, Critical reviews in clinical laboratory sciences.

[34]  D. Johnston,et al.  Detailed mapping of prostate carcinoma foci , 2000, Cancer.

[35]  G. Miller,et al.  Morphology of prostate cancer: the effects of multifocality on histological grade, tumor volume and capsule penetration. , 1994, The Journal of urology.

[36]  Alberto Riva,et al.  Defining aggressive prostate cancer using a 12-gene model. , 2006, Neoplasia.

[37]  T. Speed,et al.  Summaries of Affymetrix GeneChip probe level data. , 2003, Nucleic acids research.

[38]  M. Miyazaki,et al.  Relationship Between Pancreatic Secretory Trypsin Inhibitor and Early Recurrence of Intrahepatic Cholangiocarcinoma Following Surgical Resection , 2006, The American Journal of Gastroenterology.

[39]  M. Ringnér,et al.  Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity , 2007, Proceedings of the National Academy of Sciences.

[40]  P. Roy-Burman,et al.  Heterogeneity in intratumor distribution of p53 mutations in human prostate cancer. , 1995, The American journal of pathology.

[41]  Z. Szallasi,et al.  A signature of chromosomal instability inferred from gene expression profiles predicts clinical outcome in multiple human cancers , 2006, Nature Genetics.

[42]  J Cuzick,et al.  Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer , 2008, Oncogene.

[43]  E. Lander,et al.  A molecular signature of metastasis in primary solid tumors , 2003, Nature Genetics.

[44]  W. Gerald,et al.  Integration of gene expression profiling and clinical variables to predict prostate carcinoma recurrence after radical prostatectomy , 2005, Cancer.

[45]  C Cummings,et al.  Processing of radical prostatectomy specimens for correlation of data from histopathological, molecular biological, and radiological studies: a new whole organ technique , 2005, Journal of Clinical Pathology.

[46]  Y. Benjamini,et al.  Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .

[47]  Lei Wang,et al.  Noninvasive detection of TMPRSS2:ERG fusion transcripts in the urine of men with prostate cancer. , 2006, Neoplasia.

[48]  Michael Ittmann,et al.  Expression of variant TMPRSS2/ERG fusion messenger RNAs is associated with aggressive prostate cancer. , 2006, Cancer research.

[49]  CampbellColin,et al.  The Latent Process Decomposition of cDNA Microarray Data Sets , 2005 .

[50]  T. Stamey,et al.  Multiple cancers in the prostate. Morphologic features of clinically recognized versus incidental tumors , 1992, Cancer.

[51]  J. Cuzick,et al.  Complex patterns of ETS gene alteration arise during cancer development in the human prostate , 2008, Oncogene.

[52]  L. Klotz,et al.  Expression of TMPRSS2:ERG gene fusion in prostate cancer cells is an important prognostic factor for cancer progression , 2007, Cancer biology & therapy.

[53]  Arul M Chinnaiyan,et al.  TMPRSS2:ETV4 gene fusions define a third molecular subtype of prostate cancer. , 2006, Cancer research.

[54]  C. Cooper,et al.  Mechanisms of Disease: biomarkers and molecular targets from microarray gene expression studies in prostate cancer , 2007, Nature Clinical Practice Urology.

[55]  Lang Li,et al.  Heterogeneity of Gleason grade in multifocal adenocarcinoma of the prostate , 2004, Cancer.

[56]  R. Tibshirani,et al.  Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[57]  O. Kallioniemi,et al.  TMPRSS2 fusions with oncogenic ETS factors in prostate cancer involve unbalanced genomic rearrangements and are associated with HDAC1 and epigenetic reprogramming. , 2006, Cancer research.

[58]  G. Glinsky,et al.  Microarray analysis identifies a death-from-cancer signature predicting therapy failure in patients with multiple types of cancer. , 2005, The Journal of clinical investigation.

[59]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[60]  R. Eeles,et al.  Detection of TMPRSS2-ERG translocations in human prostate cancer by expression profiling using GeneChip Human Exon 1.0 ST arrays. , 2008, The Journal of molecular diagnostics : JMD.

[61]  T. Wheeler,et al.  Heterogeneity of prostate cancer in radical prostatectomy specimens. , 1994, Urology.

[62]  D. Bostwick,et al.  Detection of c-myc oncogene amplification and chromosomal anomalies in metastatic prostatic carcinoma by fluorescence in situ hybridization. , 1997, Cancer research.

[63]  N. Konishi,et al.  Intratumor cellular heterogeneity and alterations in ras oncogene and p53 tumor suppressor gene in human prostate carcinoma. , 1995, The American journal of pathology.

[64]  M. Rubin,et al.  TMPRSS2-ERG Fusion Prostate Cancer: An Early Molecular Event Associated With Invasion , 2006, The American journal of surgical pathology.

[65]  J. Tchinda,et al.  TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer. , 2006, Cancer research.